Metabolic changes associated with metformin potentiates Bcl-2 inhibitor, Venetoclax, and CDK9 inhibitor, BAY1143572 and reduces viability of lymphoma cells

SUPPLEMENTARY MATERIALS



Supplementary Figure 1: Metformin does not potentiate Doxorubicin. 10,000 cells (**A** Daudi, **B** SUDHL-4, **C** KPUM-UH1, **D** Jeko-1) were plated per well of a 96-well plate and treated with dose response series of both metformin (0–10 mM) and Doxorubicin (0–10 μM). Viability after 3 days was analyzed using MTS assay. Briefly 20 μL of MTS reagent was added to cells and incubated for 2 hours and absorbance at 490 nm was read using biotek plate reader. Relative absorbance is calculated after setting the average absorbance of No tx ctrl as 1.



Supplementary Figure 2: Metformin potentiates Venetoclax in cell-type dependent manner. 10,000 cells (**A** Daudi, **B** SUDHL-4, **C** KPUM-UH1, **D** Jeko-1) were plated per well of a 96-well plate and treated with dose response series of both metformin (0–10 mM) and Venetoclax (0–10 nM) Viability after 3 days was analyzed using MTS assay. Briefly 20 µL of MTS reagent was added to cells and incubated for 2 hours and absorbance at 490 nm was read using biotek plate reader. Relative absorbance is calculated after setting the average absorbance of No tx ctrl as 1.



Supplementary Figure 3: Metformin potentiates BAY-1143572 in cell-type dependent manner. 10,000 cells (**A** Daudi, **B** SUDHL-4, **C** KPUM-UH1, **D** Jeko-1) were plated per well of a 96-well plate and treated with dose response series of both metformin (0–10 mM) and BAY-1143572 (0–100 μM). Viability after 3 days was analyzed using MTS assay. Briefly 20 μL of MTS reagent was added to cells and incubated for 2 hours and absorbance at 490 nm was read using biotek plate reader. Relative absorbance is calculated after setting the average absorbance of No tx ctrl as 1.



Supplementary Figur 4: Metformin does not potentiate Idelalisib. 10,000 cells (**A** Daudi, **B** SUDHL-4, **C** KPUM-UH1, **D** Jeko-1) were plated per well of a 96-well plate and treated with dose response series of both metformin (0–10 mM) and Idelalisib (0–100 μM). Viability after 3 days was analyzed using MTS assay. Briefly 20 μL of MTS reagent was added to cells and incubated for 2 hours and absorbance at 490nm was read using biotek plate reader. Relative absorbance is calculated after setting the average absorbance of No tx ctrl as 1.



Supplementary Figure 5: Contrasted whole gel image of bcl-2 image shown in Figure 6.